“ The FBI not SEC should be investigating today'
Post# of 148169
An American company developing a highly promising drug which could save hundreds of thousands of American lives and restore our economic and social order has been attacked with intention to ruin the company and deprive the American people of the drug which would protect their health and lives.”
The M2M trial is already complete and the severe trial continues to enroll. With that being said, I’m not sure how today’s drop in the SP, or short attack, has had or will have an effect on the outcome of leronlimab and potential COVID approval. The trials will move forward and the data and the FDA will decide the outcome, not short sellers looking for a profit.